FI970058L - Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa - Google Patents

Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa Download PDF

Info

Publication number
FI970058L
FI970058L FI970058A FI970058A FI970058L FI 970058 L FI970058 L FI 970058L FI 970058 A FI970058 A FI 970058A FI 970058 A FI970058 A FI 970058A FI 970058 L FI970058 L FI 970058L
Authority
FI
Finland
Prior art keywords
omeprazole
pharmaceutical preparation
magnesium salt
preparation containing
oral pharmaceutical
Prior art date
Application number
FI970058A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970058A7 (fi
FI970058A0 (fi
Inventor
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI970058A7 publication Critical patent/FI970058A7/fi
Publication of FI970058A0 publication Critical patent/FI970058A0/fi
Publication of FI970058L publication Critical patent/FI970058L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI970058A 1994-07-08 1995-07-03 Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa FI970058L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (3)

Publication Number Publication Date
FI970058A7 FI970058A7 (fi) 1997-01-07
FI970058A0 FI970058A0 (fi) 1997-01-07
FI970058L true FI970058L (fi) 1997-01-07

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970058A FI970058L (fi) 1994-07-08 1995-07-03 Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa

Country Status (15)

Country Link
EP (1) EP0768872A1 (cs)
KR (1) KR970704426A (cs)
BR (1) BR9508261A (cs)
CA (1) CA2193681A1 (cs)
CZ (1) CZ379596A3 (cs)
EE (1) EE03378B1 (cs)
FI (1) FI970058L (cs)
HU (1) HUT78132A (cs)
IS (1) IS4398A (cs)
MX (1) MX9700152A (cs)
NO (1) NO970036L (cs)
NZ (1) NZ289958A (cs)
PL (1) PL181265B1 (cs)
SK (1) SK281803B6 (cs)
WO (1) WO1996001622A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
EP1263445A1 (en) * 2000-03-09 2002-12-11 Ian Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1755566A2 (en) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (zh) * 2015-08-19 2018-03-06 德州德药制药有限公司 一种埃索美拉唑镁肠胶囊及其制备方法
WO2022144785A1 (en) * 2020-12-30 2022-07-07 Hk Inno.N Corporation Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
HUT78132A (hu) 2000-06-28
IS4398A (is) 1996-12-17
WO1996001622A1 (en) 1996-01-25
FI970058A7 (fi) 1997-01-07
EE9700014A (et) 1997-06-16
EE03378B1 (et) 2001-04-16
EP0768872A1 (en) 1997-04-23
PL318464A1 (en) 1997-06-09
NO970036D0 (no) 1997-01-06
FI970058A0 (fi) 1997-01-07
WO1996001622A8 (en) 1999-12-23
NO970036L (no) 1997-01-06
AU695723B2 (en) 1998-08-20
PL181265B1 (pl) 2001-06-29
BR9508261A (pt) 1997-12-23
SK281803B6 (sk) 2001-08-06
SK166096A3 (en) 1997-09-10
AU2994795A (en) 1996-02-09
NZ289958A (en) 1998-09-24
HU9700039D0 (en) 1997-02-28
CA2193681A1 (en) 1996-01-25
KR970704426A (ko) 1997-09-06
MX9700152A (es) 1997-04-30
CZ379596A3 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
FI970058A7 (fi) Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omep ratsolin magnesiumsuolaa
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
ATE206924T1 (de) Oral anzuwendende arzneizubereitung enthaltend olanzapin
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
DK0936913T4 (da) Oralt farmaceutisk præparat indeholdende ibandronat
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
FI964682L (fi) Glukagonia sisältävä farmaseuttinen valmiste
FI970995L (fi) Farmaseuttisia yhdisteitä
FI971018L (fi) Farmaseuttisia yhdisteitä
FI954243A7 (fi) Farmaseuttiset yhdisteet
FI930272L (fi) Oral osmotisk anordning som loesger nikotin
FI910088L (fi) Oral farmaceutisk komposition.
DK290989D0 (da) Farmaceutisk praeparat mod nephritis
NO975680L (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
FI951155A7 (fi) Farmaseuttinen valmiste
FI964918L (fi) Lääkeainesuoloja
EE200000401A (et) Farmatseutilise preparaadi valmistamismeetod
FI903885A0 (fi) Ny oral farmaceutisk doseringsform som foerbaettrar biotillgaengligheten.
SE9402433D0 (sv) New oral pharmaceutical dosage form
EP0790829A4 (en) Medicaments
NO20003284D0 (no) Farmasøytisk preparat for oral administrering
SE9402432D0 (sv) New pharmaceutical dosage form
SE9402925D0 (sv) Novel oral pharmaceutical composition
ZA917309B (en) New oral drug forms
NO962816D0 (no) Farmasöytiske forbindelser